As the $1 trln drugmaker’s smash-hit obesity treatments shrink waistlines, its cashflow and valuation are swelling. Gilead, Moderna and Pfizer show how hard it is to put such a windfall to good ...
Hosted on MSN
Eli Lilly's retatrutide is so hot, the unlaunched weight-loss drug is already getting knocked off
Eli Lilly's new weight-loss drug is creating so much buzz that Shenelle Rodriguez found a way to get ahold of the obesity treatment — even though it's not yet approved. Under normal circumstances, the ...
Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial control of breast cancer drug Verzenios, a shift that raises fresh questions about how the stock’s ...
A U.S. appeals court revived a lawsuit brought by Teva that accuses Eli Lilly of breaching a settlement agreement that ...
The company is using that money to plan for the future. Eli Lilly has been making strategic acquisitions, mostly outside of its core area of expertise. Thanks to these deals, it has bolstered its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results